Latest C-Raf Stories
Neural stem cells transplanted into tumor-bearing rats can hinder tumor cell growth and prolife-ration; however, the mechanism remains unclear.
A new study reveals a single mutation, known as BRAF V600E, occurred in every patient in a group with hairy cell leukemia, suggesting this mutation could have implications for treating the disease.
Researchers at the Institute for Research in Immunology and Cancer (IRIC) of the UniversitÃ© de MontrÃ©al have identified a new mechanism controlling the transmission of an abnormal signal at the origin of several cancers.
CARLSBAD, Calif., Feb.
New kinase array designed for drug screening, substrate profiling and kinase interaction discovery VANCOUVER, Feb. 10 /PRNewswire/ - Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening.
LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Florida corporation, announce the signature of an exclusive license agreement for the development and commercialization of Debio 0928, a small molecule in early preclinical development that inhibits the...
Scientists have uncovered an interesting connection between two important protein kinase signaling pathways that are associated with cancer. The research, published by Cell Press in the January 30th issue of the journal Molecular Cell, may direct new therapeutic strategies for multiple types of cancer.
Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844.
Ardea Biosciences has announced positive data from a preclinical study of RDEA119, the company's lead mitogen-activated ERK kinase inhibitor, which showed the product candidate to be a promising investigational therapy for inflammatory diseases.
- An armed gangster.